Medical Devices & Diagnostics / Digital Health Imaging
Strategic Profile
The company offers Nanox.MARKETPLACE connecting imaging facilities with radiologists, Nanox.CONNECT for regulatory approvals, and AI-based imaging solutions designed to identify or predict undiagnosed medical conditions. Nano-X's collaboration with 3DR Labs integrates its FDA-cleared AI tools into a portfolio reaching over 1,800 U.S. hospitals, representing a pivotal step in scaling AI imaging solutions.
Cyborg Score Rationale
The company has experienced revenue growth of 92.3% over the past three years, indicating strong upward trajectory. However, profitability metrics are concerning, with an operating margin of -485.4% and net margin of -468.29%, highlighting significant operational challenges. An Altman Z-Score of 1.93 places the company in the grey area of financial stress.
Top Insights
Nano-X projects substantial revenue increase to $35 million by 2026, exceeding market expectations.
Company recently secured FDA 510(k) clearance for TAP2D image enhancement on Nanox.ARC systems in February 2026.
Nano-X Imaging trades at a price-to-sales ratio of 18.6x, dramatically higher than the US Healthcare industry average of 1.3x, signaling elevated risk if growth expectations are not met.
Strong liquidity position with a current ratio of 4.19 and quick ratio of 4.03.
Named Competitors
Computed Tomography Systems — Traditional medical imaging and diagnostic solutions
Digital Radiography — Established imaging and healthcare IT platforms
AI Imaging Diagnostics — AI-driven medical imaging analysis
Recent Developments
(February 2026) FDA 510(k) Clearance for TAP2D Image Enhancement on Nanox.ARC systems
(November 2025) Acquisition of VasoHealthCareIT and strategic partnership with 3DR Labs for AI distribution